Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)

BACKGROUND: Treatment of spasticity poses a major challenge in amyotrophic lateral sclerosis (ALS) patient management. Delta-9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (THC:CBD), approved for the treatment of spasticity in multiple sclerosis, serves as a complementary off-label...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Thomas, Funke, Andreas, Münch, Christoph, Kettemann, Dagmar, Maier, André, Walter, Bertram, Thomas, Annett, Spittel, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732193/
https://www.ncbi.nlm.nih.gov/pubmed/31493784
http://dx.doi.org/10.1186/s12883-019-1443-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732193/
https://www.ncbi.nlm.nih.gov/pubmed/31493784
http://dx.doi.org/10.1186/s12883-019-1443-y

Ejemplares similares